SMC Accepts First Drug to Improve Survival in Uveal Melanoma
Medscape,
The Scottish Medicines Consortium (SMC) has accepted tebentafusp (Kimmtrak, Immunocore Ltd) for use within NHS Scotland as…
Tebentafusp Maintains OS Benefit in HLA-A*02:01+ Uveal Melanoma
UBM Medica,
Paul Nathan, MBBS, PhD, MCRP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01-positive…
Tebentafusp Yields Favorable 5-Year OS Data in HLA-A*02:01+ Uveal Melanoma
Cancer Network,
The 5-year survival rate was favorable with tebentafusp-tebn (Kimmtrak) compared with investigator’s choice of therapy (ICT…
Tebentafusp Yields Favorable 5-Year OS Data in HLA-A*02:01+ Uveal Melanoma
UBM Medica,
The 5-year OS rate was 16% vs 8% between the tebentafusp and control arms for patients with HLA-A*02:01-positive uveal melanoma.